Cepheid's Q3 Revenues Fall 7 Percent on Lower Systems Sales; Beat Estimates

Cepheid beat analysts' estimates on the top and bottom line, partially due to lower R&D spending.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.